The Androgen Receptor is a negative regulator of eIF4E Phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer

The anti-androgen bicalutamide is widely used in the treatment of advanced prostate cancer (PCa) in many countries, but its effect on castration resistant PCa (CRPC) is limited. We previously showed that resistance to bicalutamide results from activation of mechanistic target of rapamycin (mTOR). In...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: D’Abronzo, Leandro S., Bose, Swagata, Crapuchettes, Michael E., Beggs, Ryan E., Vinall, Ruth L., Tepper, Clifford G., Siddiqui, Salma, Mudryj, Maria, Melgoza, Frank U., Durbin-Johnson, Blythe P., deVere White, Ralph W., Ghosh., Paramita M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690844/
https://ncbi.nlm.nih.gov/pubmed/28745319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.233
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados